For decades, oncology has operated on a fundamental compromise: treating heterogeneous tumors with therapies designed for an averaged patient. Single-cell technology — accelerated by artificial intelligence — is finally rewriting that contract between biology and medicine.
Introduction
The Limitations of Bulk Sequencing
Traditional bulk sequencing analyzes thousands of cells as a single homogenous sample, producing an averaged signal that obscures the very heterogeneity that defines cancer. A single tumor can harbor dozens of genetically distinct subpopulations, each with unique vulnerabilitiesand resistance mechanisms.
This averaging effect has historically been the silent saboteur of clinical trials. Therapies that appear ineffective in aggregate may, in fact, be highly potent against specific cellular subtypes— subtypes we simply could not see.
- Bulk RNA-seq masks rare but clinically critical cell populations.
- Tumor microenvironment signals are diluted beyond recognition.
- Drug-resistance precursors remain invisible until relapse occurs.
Methodology
Where Artificial Intelligence Enters the Frame
A single experiment now generates data on hundreds of thousands of cells, each described by tens of thousands of features. The resulting dimensionality is not just large — it is biologically combinatorial. No human team can manually identify the patterns that distinguish a treatment-responsive clone from one that will drive recurrence three years later.
This is precisely the problem deep learning was built to solve. Foundation models trained on tens of millions of single-cell profiles can now infer cell type, state, lineage trajectory, and drug response with accuracies that exceed expert pathologists in benchmark studies.
“We are no longer asking what a tumor is. We are asking
what each of its cells intends to do next — and
intervening before it can.”
— Dr. Anjali Verma, CSO
Three architectural breakthroughs
Recent advances have made clinical-grade single-cell AI viable at scale. Transformer-based encoders trained on cross-tissue atlases generalize across cancer types. Graph neural networks model cell-cell signaling within the tumor microenvironment. And contrastive learning alignssingle-cell signatures with clinical outcomes drawn from millions of patient records.
- 94% Diagnostic concordance with expert pathology in blinded trials
- 10M+ Single-cell profiles in our pre-trained foundation model
- 7× Faster therapy stratification vs. conventional workflows
